Beijing Aoyuan Heli Biotechnology

Beijing Aoyuan Heli Biotechnology is a clinical-stage Chinese biopharmaceutical company specializing in the development of innovative gene therapy products. The company's core expertise lies in its proprietary adenoviral and herpes simplex virus (HSV) vector platforms, which it utilizes to create treatments for cardiovascular and metabolic diseases. Its lead candidate, Alenpermin (pAd-hHGF), is a recombinant human hepatocyte growth factor adenovirus injection designed to treat critical limb ischemia and has successfully completed Phase 3 clinical trials in China. Founded in 2005, Aoyuan Heli is a pioneer in the domestic gene therapy landscape, focusing on addressing significant unmet medical needs in chronic ischemic conditions. The company is headquartered in Beijing and has established a comprehensive R&D and manufacturing infrastructure for biological drugs.